Every month the noise gets louder and the signal gets quieter. This is the signal — three threads worth a clinician's attention, and what to do with each.
The interesting GLP-1 conversation has moved on from titration. The work now is maintenance — the literature is trending toward lower-dose, longer-interval protocols after patients hit goal, and toward preserving lean mass during the run. The practices asking "what does year two look like?" are the ones building durable programs. Watch dosing intervals, not just doses, and budget the follow-up infrastructure before the demand arrives.
The recovery science this month says the same thing it said last month, which is the point: regularity is beating intensity everywhere it's measured. Fixed wake times are outperforming total sleep hours on metabolic markers; zone 2 base work is compounding under every strength program that sits on top of it. The lesson for practice owners: sell the schedule, not the session.
Overnight glucose stability is having its moment — late meals are measurably blunting next-morning insulin sensitivity, and the practical protocol is refreshingly boring: kitchen closes three hours before bed, protein-forward dinner, no alcohol within that window. For practices running continuous glucose monitors, the overnight trace is becoming the fastest honest report card on a patient's week.
Fear marketing. Miracle stacks. Anything that explains a complicated system in one sentence. The category is moving fast enough that the boring, measured version of the story is the interesting one.
The reading is what PrimeBodyMind is for — the practice machinery behind it, from sourcing to documentation, is what PrescribeUSA runs.